A new prototype for a device that both clears blood vessels of blockage and precisely delivers anti-blockage medication or live cells to the site,has been developed by Atlanta Catheter Therapies.The Occlusion Perfusion Catheter follows the guide wire used by the de-bulking catheter to deliver therapy to the treatment site.
Re-blocking of blood vessels,or restinosis,is a major problem in cardiovascular medicine.Restinosis occurs when smooth muscle cells migrate to the blood vessels and proliferate there,having been stirred up by the catheterization procedure itself,which amounts to a controlled injury to blood vessel walls.More surgery is then indicated,costing the health care system an estimated 475 billion dollars a year.Effectively delivering anti-blockage therapy has been a significant dilemma to this point.
ACT specializes in the development of new technology for catheterization procedures.It brings the new device to the human trials stage.At that time,the work is licensed or sold to a strategic partner.The company is led by CEO Paul Fitzpatrick.Mr.Fitzpatrick joined the firm on March 12.He has 24 years of experience in the entrepreneurial health care field,including start-ups,turn-arounds and integration.
No comments:
Post a Comment